TP53_PROF: a machine learning model to predict impact of missense mutations in TP53

被引:10
|
作者
Ben-Cohen, Gil [2 ]
Doffe, Flora [3 ]
Devir, Michal [2 ]
Leroy, Bernard [4 ]
Soussi, Thierry [4 ]
Rosenberg, Shai [1 ,5 ,6 ]
机构
[1] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Jerusalem, Israel
[3] Univ Paris Saclay, Gif Sur Yvette, France
[4] Sorbonne Univ, Paris, France
[5] Hebrew Univ Jerusalem, Gaffin Ctr Neurooncol, Sharett Inst Oncol, Hadassah Med Ctr, Jerusalem, Israel
[6] Hebrew Univ Jerusalem, Wohl Inst Translat Med, Hadassah Med Ctr, Jerusalem, Israel
关键词
TP53; genetic counseling; Li-Fraumeni syndrome; precision medicine; personalized oncology; machine learning; DNA-BINDING COOPERATIVITY; P53; DATABASE; PROTEIN; OLIGOMERIZATION; RECOMMENDATIONS; CONFORMATION; REASSESSMENT; INHIBITION; LANDSCAPE;
D O I
10.1093/bib/bbab524
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Correctly identifying the true driver mutations in a patient's tumor is a major challenge in precision oncology. Most efforts address frequent mutations, leaving medium- and low-frequency variants mostly unaddressed. For TP53, this identification is crucial for both somatic and germline mutations, with the latter associated with the Li-Fraumeni syndrome (LFS), a multiorgan cancer predisposition. We present TP53_PROF (prediction of functionality), a gene specific machine learning model to predict the functional consequences of every possible missense mutation in TP53, integrating human cell- and yeast-based functional assays scores along with computational scores. Variants were labeled for the training set using well-defined criteria of prevalence in four cancer genomics databases. The model's predictions provided accuracy of 96.5%. They were validated experimentally, and were compared to population data, LFS datasets, ClinVar annotations and to TCGA survival data. Very high accuracy was shown through all methods of validation. TP53_PROF allows accurate classification of TP53 missense mutations applicable for clinical practice. Our gene specific approach integrated machine learning, highly reliable features and biological knowledge, to create an unprecedented, thoroughly validated and clinically oriented classification model. This approach currently addresses TP53 mutations and will be applied in the future to other important cancer genes.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] TP53 mutations: the dawn of Shwachman clones
    Donadieu, Jean
    Delhommeau, Francois
    BLOOD, 2018, 131 (04) : 376 - 377
  • [42] Patterns of mutations in TP53 mutated AML
    Welch, John S.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (04) : 379 - 383
  • [43] TP53 mutations and Polymorphisms in Primary Myelofibrosis
    Raza, Sania S.
    Viswanatha, David
    Erickson, Lori A.
    Lasho, Terra L.
    Finke, Christy
    Knudson, Ryan A.
    Ketterling, Rhett
    Pardanani, Animesh D.
    Tefferi, Ayalew
    BLOOD, 2011, 118 (21) : 1641 - 1641
  • [44] TP53 mutations in human skin cancers
    Giglia-Mari, G
    Sarasin, A
    HUMAN MUTATION, 2003, 21 (03) : 217 - 228
  • [45] TP53 mutations in head and neck cancer
    Beutner, Dirk
    Klussmann, Jens-Peter
    Guntinas-Lichius, Orlando
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11): : 1194 - 1194
  • [46] TP53 MUTATIONS ARE IMMUNOGENIC IN EPITHELIAL CANCER
    不详
    CANCER DISCOVERY, 2019, 9 (04) : 461 - 461
  • [47] TP53 mutations in head and neck cancer
    Nathan, Cherie-Ann
    Khandelwal, Alok R.
    Wolf, Gregory T.
    Rodrigo, Juan P.
    Makitie, Antti A.
    Saba, Nabil F.
    Forastiere, Arlene A.
    Bradford, Carol R.
    Ferlito, Alfio
    MOLECULAR CARCINOGENESIS, 2022, 61 (04) : 385 - 391
  • [48] Smoking, lung cancers and their TP53 mutations
    Cooper, CS
    MUTAGENESIS, 2002, 17 (04) : 279 - 280
  • [49] TP53 mutations and MDS - not as easy as it seems
    Haase, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 7 - 8
  • [50] TP53 Mutations in Uterine Atypical Leiomyomas
    Kuhn, E.
    Yemelyanova, A.
    Wang, T-L
    Kurman, R. J.
    Shih, I-M
    LABORATORY INVESTIGATION, 2012, 92 : 281A - 282A